Martin E. Sanders
59Patents
10h-index
22Co-inventors
78Inventor score
Filing activity: Aug 27, 1985 → Jan 18, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9907768B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 24 | Active |
| US10004708B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 18 | Active |
| US10004709B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 18 | Active |
| US8377435B2 | Antibody induced cell membrane wounding | Chemistry; Metallurgy | 18 | Active |
| US9458241B2 | Antibody induced cell membrane wounding | Chemistry; Metallurgy | 17 | Active |
| US10213401B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 15 | Active |
| US6015786A | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 | Human Necessities | 14 | Expired |
| US10231944B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 13 | Active |
| US10835507B2 | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones | Human Necessities | 11 | Active |
| US6025368A | Method for treating the symptoms of chronic stress-related disorders using IGF | Human Necessities | 11 | Expired |
| US10471030B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 10 | Active |
| US10966950B2 | Use of an RXR agonist in treating HER2+ cancers | Human Necessities | 10 | Active |
| US10123982B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 10 | Active |
| US10363272B2 | RAR selective agonists in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 9 | Active |
| US10485775B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 9 | Active |
| US10532074B2 | RAR selective agonists in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 8 | Active |
| US10973791B2 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | Emerging Cross-Sectional Technologies | 7 | Active |
| US10857117B2 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | Emerging Cross-Sectional Technologies | 7 | Active |
| US10806713B2 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | Emerging Cross-Sectional Technologies | 7 | Active |
| US10980759B2 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | Emerging Cross-Sectional Technologies | 7 | Active |
| US11065219B2 | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | Emerging Cross-Sectional Technologies | 7 | Active |
| US10517843B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 6 | Active |
| US4722890A | Quantitative assay for human terminal complement cascade activation | Emerging Cross-Sectional Technologies | 5 | Expired |
| US10874627B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US10874628B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Chemistry; Metallurgy | 3 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.